Specialty Drug Basics
What percentage of prescriptions are specialty drugs?
1-2%
What payment type requires patients to pay a percentage of drug cost?
Coinsurance
What is financial toxicity?
Financial costs caused by medical costs
What program provides drug coverage for Medicare patients?
Medicare Part D
Which group benefits the most from lower drug costs?
Patients
What percentage of total drug spending do specialty drugs account for?
40-50%
What payment type is a fixed amount per prescription?
Copay
What behavior occurs when patients can't afford medications?
Non adherence
What percentage of coinsurance do many Part D patients pay?
25-33%
What policy replaces percentage-based payments with fixed costs?
Copays instead of coinsurance
What montly cost allows for a prescription to be categorized as "specialty"
$670 or more per month
What must patients pay before insurance begins covering costs?
Deductible
Name one consequence of financial toxicity
Debt, borrowing money, worse outcomes, and reduced adherence
What major feature is missing from Medicare Part D?
A true out-of-pocket gap
What are PBMS?
Key stakeholders who determine which specialty drugs are covered and negotiate deals that may increase patient costs.
Name one condition treated by specialty drugs
Cancer, Hepatitis etc
What trend has increased patient financial burden?
How does cost affect health outcomes?
Leads to worse outcomes due to non adherence
Are deductibles required?
Yes
What is regulating drug pricing and negotiation?
Greater government involvement to lower drug costs by allowing negotiation and setting limits on prices
Why are specialty drugs considered complex?
They require special handling and monitoring or treat serious conditions
Why does coinsurance create higher costs for specialty drugs?
Patients pay a percentage of very high drug prices
Why is financial toxicity considered a healthcare issue?
It directly impacts treatment access and patient outcomes
Why is the lack of a cap a problem?
Patients can face unlimited out-of-pocket costs
Shift financial risk away from patients and toward insurers and pharmaceutical companies by replacing percentage-based cost sharing with predictable pricing
- also requiring greater transparency to address power imbalances among key stakeholders